Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

EPHA2 Receptor as a Possible Therapeutic Target in Viral Infections

Author(s): Marian Vincenzi, Flavia Anna Mercurio and Marilisa Leone*

Volume 31, Issue 35, 2024

Published on: 11 October, 2023

Page: [5670 - 5701] Pages: 32

DOI: 10.2174/0109298673256638231003111234

Price: $65

Abstract

Background: The receptor tyrosine kinase EphA2 plays a role in many diseases, like cancer, cataracts, and osteoporosis. Interestingly, it has also been linked to viral infections.

Objective: Herein, current literature has been reviewed to clarify EphA2 functions in viral infections and explore its potential role as a target in antiviral drug discovery strategies.

Methods: Research and review articles along with preprints connecting EphA2 to different viruses have been searched through PubMed and the web. Structures of complexes between EphA2 domains and viral proteins have been retrieved from the PDB database.

Results: EphA2 assumes a key role in Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein Barr virus (EBV) infections by directly binding, through its ligand binding domain, viral glycoproteins. For human cytomegalovirus (HCMV), the role of EphA2 in maintaining virus latency state, through cooperation with specific viral proteins, has also been speculated. In certain cells, with high EphA2 expression levels, following ligand stimulation, receptor activation might contribute to severe symptoms accompanying a few viral infections, including lung injuries often related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Conclusion: Since EphA2 works as a host receptor for certain viruses, it might be worth more deeply investigating known compounds targeting its extracellular ligand binding domain as antiviral therapeutics. Due to EphA2's function in inflammation, its possible correlation with SARS-CoV-2 cannot be excluded, but more experimental studies are needed in this case to undoubtedly attribute the role of this receptor in viral infections.

« Previous Next »
[1]
Du, Z.; Lovly, C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer, 2018, 17(1), 58.
[http://dx.doi.org/10.1186/s12943-018-0782-4] [PMID: 29455648]
[2]
Park, J.; Son, A.; Zhou, R. Roles of EphA2 in development and disease. Genes (Basel), 2013, 4(3), 334-357.
[http://dx.doi.org/10.3390/genes4030334] [PMID: 24705208]
[3]
Hubbard, S.R.; Miller, W.T. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin. Cell Biol., 2007, 19(2), 117-123.
[http://dx.doi.org/10.1016/j.ceb.2007.02.010] [PMID: 17306972]
[4]
Darling, T.K.; Lamb, T.J. Emerging roles for Eph receptors and ephrin ligands in immunity. Front. Immunol., 2019, 10, 1473.
[http://dx.doi.org/10.3389/fimmu.2019.01473] [PMID: 31333644]
[5]
Pasquale, E.B. The Eph family of receptors. Curr. Opin. Cell Biol., 1997, 9(5), 608-615.
[http://dx.doi.org/10.1016/S0955-0674(97)80113-5] [PMID: 9330863]
[6]
Mercurio, F.A.; Vincenzi, M.; Leone, M. Hunting for novel routes in anticancer drug discovery: Peptides against Sam-Sam interactions. Int. J. Mol. Sci., 2022, 23(18), 10397.
[http://dx.doi.org/10.3390/ijms231810397] [PMID: 36142306]
[7]
Zhou, Y.; Sakurai, H. Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression. Biol. Pharm. Bull., 2017, 40(10), 1616-1624.
[http://dx.doi.org/10.1248/bpb.b17-00446] [PMID: 28966234]
[8]
Wilson, K.; Shiuan, E.; Brantley-Sieders, D.M. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene, 2021, 40(14), 2483-2495.
[http://dx.doi.org/10.1038/s41388-021-01714-8] [PMID: 33686241]
[9]
Lisabeth, E.M.; Falivelli, G.; Pasquale, E.B. Eph receptor signaling and ephrins. Cold Spring Harb. Perspect. Biol., 2013, 5(9), a009159.
[http://dx.doi.org/10.1101/cshperspect.a009159] [PMID: 24003208]
[10]
Mercurio, F.; Leone, M. The Sam domain of EphA2 receptor and its relevance to cancer: A novel challenge for drug discovery? Curr. Med. Chem., 2016, 23(42), 4718-4734.
[http://dx.doi.org/10.2174/0929867323666161101100722] [PMID: 27804871]
[11]
Sahoo, A.R.; Buck, M. Structural and functional insights into the transmembrane domain association of Eph receptors. Int. J. Mol. Sci., 2021, 22(16), 8593.
[http://dx.doi.org/10.3390/ijms22168593] [PMID: 34445298]
[12]
Seiradake, E.; Harlos, K.; Sutton, G.; Aricescu, A.R.; Jones, E.Y. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat. Struct. Mol. Biol., 2010, 17(4), 398-402.
[http://dx.doi.org/10.1038/nsmb.1782] [PMID: 20228801]
[13]
Lechtenberg, B.C.; Gehring, M.P.; Light, T.P.; Horne, C.R.; Matsumoto, M.W.; Hristova, K.; Pasquale, E.B. Regulation of the EphA2 receptor intracellular region by phosphomimetic negative charges in the kinase-SAM linker. Nat. Commun., 2021, 12(1), 7047.
[http://dx.doi.org/10.1038/s41467-021-27343-z] [PMID: 34857764]
[14]
Mirdita, M.; Schütze, K.; Moriwaki, Y.; Heo, L.; Ovchinnikov, S.; Steinegger, M. ColabFold: Making protein folding accessible to all. Nat. Methods, 2022, 19(6), 679-682.
[http://dx.doi.org/10.1038/s41592-022-01488-1] [PMID: 35637307]
[15]
Bateman, A.; Martin, M-J.; Orchard, S.; Magrane, M.; Ahmad, S.; Alpi, E.; Bowler-Barnett, E.H.; Britto, R.; Bye-A-Jee, H.; Cukura, A.; Denny, P.; Dogan, T.; Ebenezer, T.G.; Fan, J.; Garmiri, P.; da Costa Gonzales, L.J.; Hatton-Ellis, E.; Hussein, A.; Ignatchenko, A.; Insana, G.; Ishtiaq, R.; Joshi, V.; Jyothi, D.; Kandasaamy, S.; Lock, A.; Luciani, A.; Lugaric, M.; Luo, J.; Lussi, Y.; MacDougall, A.; Madeira, F.; Mahmoudy, M.; Mishra, A.; Moulang, K.; Nightingale, A.; Pundir, S.; Qi, G.; Raj, S.; Raposo, P.; Rice, D.L.; Saidi, R.; Santos, R.; Speretta, E.; Stephenson, J.; Totoo, P.; Turner, E.; Tyagi, N.; Vasudev, P.; Warner, K.; Watkins, X.; Zaru, R.; Zellner, H.; Bridge, A.J.; Aimo, L.; Argoud-Puy, G.; Auchincloss, A.H.; Axelsen, K.B.; Bansal, P.; Baratin, D.; Batista Neto, T.M.; Blatter, M-C.; Bolleman, J.T.; Boutet, E.; Breuza, L.; Gil, B.C.; Casals-Casas, C.; Echioukh, K.C.; Coudert, E.; Cuche, B.; de Castro, E.; Estreicher, A.; Famiglietti, M.L.; Feuermann, M.; Gasteiger, E.; Gaudet, P.; Gehant, S.; Gerritsen, V.; Gos, A.; Gruaz, N.; Hulo, C.; Hyka-Nouspikel, N.; Jungo, F.; Kerhornou, A.; Le Mercier, P.; Lieberherr, D.; Masson, P.; Morgat, A.; Muthukrishnan, V.; Paesano, S.; Pedruzzi, I.; Pilbout, S.; Pourcel, L.; Poux, S.; Pozzato, M.; Pruess, M.; Redaschi, N.; Rivoire, C.; Sigrist, C.J.A.; Sonesson, K.; Sundaram, S.; Wu, C.H.; Arighi, C.N.; Arminski, L.; Chen, C.; Chen, Y.; Huang, H.; Laiho, K.; McGarvey, P.; Natale, D.A.; Ross, K.; Vinayaka, C.R.; Wang, Q.; Wang, Y.; Zhang, J. UniProt: The universal protein knowledgebase in 2023. Nucleic Acids Res., 2023, 51(D1), D523-D531.
[http://dx.doi.org/10.1093/nar/gkac1052] [PMID: 36408920]
[16]
Hedger, G.; Sansom, M.S.P.; Koldsø, H. The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids. Sci. Rep., 2015, 5(1), 9198.
[http://dx.doi.org/10.1038/srep09198] [PMID: 25779975]
[17]
Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera? A visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25(13), 1605-1612.
[http://dx.doi.org/10.1002/jcc.20084] [PMID: 15264254]
[18]
Xiao, T.; Xiao, Y.; Wang, W.; Tang, Y.Y.; Xiao, Z.; Su, M. Targeting EphA2 in cancer. J. Hematol. Oncol., 2020, 13(1), 114.
[http://dx.doi.org/10.1186/s13045-020-00944-9] [PMID: 32811512]
[19]
Zhao, P.; Jiang, D.; Huang, Y.; Chen, C. EphA2: A promising therapeutic target in breast cancer. J. Genet. Genomics, 2021, 48(4), 261-267.
[http://dx.doi.org/10.1016/j.jgg.2021.02.011] [PMID: 33962882]
[20]
Coulthard, M.G.; Morgan, M.; Woodruff, T.M.; Arumugam, T.V.; Taylor, S.M.; Carpenter, T.C.; Lackmann, M.; Boyd, A.W. Eph/Ephrin signaling in injury and inflammation. Am. J. Pathol., 2012, 181(5), 1493-1503.
[http://dx.doi.org/10.1016/j.ajpath.2012.06.043] [PMID: 23021982]
[21]
Funk, S.D.; Orr, A.W. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacol. Res., 2013, 67(1), 42-52.
[http://dx.doi.org/10.1016/j.phrs.2012.10.008] [PMID: 23098817]
[22]
Arthur, A.; Gronthos, S. Eph-ephrin signaling mediates cross-talk within the bone microenvironment. Front. Cell Dev. Biol., 2021, 9, 598612.
[http://dx.doi.org/10.3389/fcell.2021.598612] [PMID: 33634116]
[23]
Jin, S.; Yan, Z.; Tieyi, Y.; Shuyi, L.; Liang, W.; Hui, Y. Eph–ephrin bidirectional signalling: A promising approach for osteoporosis treatment. J. Medical Hypotheses Ideas, 2013, 7(2), 40-42.
[http://dx.doi.org/10.1016/j.jmhi.2013.02.002]
[24]
Bennett, T.M.; M’Hamdi, O.; Hejtmancik, J.F.; Shiels, A. Germ-line and somatic EphA2 coding variants in lens aging and cataract. PLoS One, 2017, 12(12), e0189881.
[http://dx.doi.org/10.1371/journal.pone.0189881] [PMID: 29267365]
[25]
Zhang, T.; Hua, R.; Xiao, W.; Burdon, K.P.; Bhattacharya, S.S.; Craig, J.E.; Shang, D.; Zhao, X.; Mackey, D.A.; Moore, A.T.; Luo, Y.; Zhang, J.; Zhang, X. Mutations of the EphA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum. Mutat., 2009, 30(5), E603-E611.
[http://dx.doi.org/10.1002/humu.20995] [PMID: 19306328]
[26]
Shiels, A.; Bennett, T.M.; Knopf, H.L.; Maraini, G.; Li, A.; Jiao, X.; Hejtmancik, J.F. The EPHA2 gene is associated with cataracts linked to chromosome 1p. Mol. Vis., 2008, 14, 2042-2055.
[PMID: 19005574]
[27]
Su, C.; Wu, L.; Chai, Y.; Qi, J.; Tan, S.; Gao, G.F.; Song, H.; Yan, J. Molecular basis of EphA2 recognition by gHgL from gamma herpesviruses. Nat. Commun., 2020, 11(1), 5964.
[http://dx.doi.org/10.1038/s41467-020-19617-9] [PMID: 33235207]
[28]
Chen, J.; Schaller, S.; Jardetzky, T.S.; Longnecker, R. Epstein-barr virus gH/gL and Kaposi’s sarcoma-associated herpesvirus gH/gL bind to different sites on EphA2 to trigger fusion. J. Virol., 2020, 94(21), e01454-20.
[http://dx.doi.org/10.1128/JVI.01454-20] [PMID: 32847853]
[29]
Möhl, B.S.; Chen, J.; Longnecker, R. Gammaherpesvirus entry and fusion: A tale how two human pathogenic viruses enter their host cells. Adv. Virus Res., 2019, 104, 313-343.
[http://dx.doi.org/10.1016/bs.aivir.2019.05.006] [PMID: 31439152]
[30]
Shin, J.M.; Han, M.S.; Park, J.H.; Lee, S.H.; Kim, T.H.; Lee, S.H. The EphA1 and EphA2 signaling modulates the epithelial permeability in human sinonasal epithelial cells and the rhinovirus infection induces epithelial barrier dysfunction via EphA2 receptor signaling. Int. J. Mol. Sci., 2023, 24(4), 3629.
[http://dx.doi.org/10.3390/ijms24043629] [PMID: 36835041]
[31]
Lupberger, J.; Zeisel, M.B.; Xiao, F.; Thumann, C.; Fofana, I.; Zona, L.; Davis, C.; Mee, C.J.; Turek, M.; Gorke, S.; Royer, C.; Fischer, B.; Zahid, M.N.; Lavillette, D.; Fresquet, J.; Cosset, F.L.; Rothenberg, S.M.; Pietschmann, T.; Patel, A.H.; Pessaux, P.; Doffoël, M.; Raffelsberger, W.; Poch, O.; McKeating, J.A.; Brino, L.; Baumert, T.F. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med., 2011, 17(5), 589-595.
[http://dx.doi.org/10.1038/nm.2341] [PMID: 21516087]
[32]
Light, T.P.; Brun, D.; Guardado-Calvo, P.; Pederzoli, R.; Haouz, A.; Neipel, F.; Rey, F.A.; Hristova, K.; Backovic, M. Human herpesvirus 8 molecular mimicry of ephrin ligands facilitates cell entry and triggers EphA2 signaling. PLoS Biol., 2021, 19(9), e3001392.
[http://dx.doi.org/10.1371/journal.pbio.3001392] [PMID: 34499637]
[33]
Beauchamp, A.; Debinski, W. Ephs and ephrins in cancer: Ephrin-A1 signalling. Semin. Cell Dev. Biol., 2012, 23(1), 109-115.
[http://dx.doi.org/10.1016/j.semcdb.2011.10.019] [PMID: 22040911]
[34]
Nasreen, N.; Khodayari, N.; Mohammed, K.A. Advances in malignant pleural mesothelioma therapy: Targeting EphA2 a novel approach. Am. J. Cancer Res., 2012, 2(2), 222-234.
[PMID: 22432060]
[35]
London, M.; Gallo, E. The EphA2 and cancer connection: Potential for immune-based interventions. Mol. Biol. Rep., 2020, 47(10), 8037-8048.
[http://dx.doi.org/10.1007/s11033-020-05767-y] [PMID: 32990903]
[36]
Psilopatis, I.; Pergaris, A.; Vrettou, K.; Tsourouflis, G.; Theocharis, S. The EPH/Ephrin system in gynecological cancers: Focusing on the roots of carcinogenesis for better patient management. Int. J. Mol. Sci., 2022, 23(6), 3249.
[http://dx.doi.org/10.3390/ijms23063249] [PMID: 35328669]
[37]
Tandon, M.; Vemula, S.V.; Mittal, S.K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther. Targets, 2011, 15(1), 31-51.
[http://dx.doi.org/10.1517/14728222.2011.538682] [PMID: 21142802]
[38]
Zhuang, G.; Hunter, S.; Hwang, Y.; Chen, J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J. Biol. Chem., 2007, 282(4), 2683-2694.
[http://dx.doi.org/10.1074/jbc.M608509200] [PMID: 17135240]
[39]
Buckens, O.J.; El Hassouni, B.; Giovannetti, E.; Peters, G.J. The role of Eph receptors in cancer and how to target them: Novel approaches in cancer treatment. Expert Opin. Investig. Drugs, 2020, 29(6), 567-582.
[http://dx.doi.org/10.1080/13543784.2020.1762566] [PMID: 32348169]
[40]
Giorgio, C.; Hassan Mohamed, I.; Flammini, L.; Barocelli, E.; Incerti, M.; Lodola, A.; Tognolini, M. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS One, 2011, 6(3), e18128.
[http://dx.doi.org/10.1371/journal.pone.0018128] [PMID: 21479221]
[41]
Giorgio, C.; Russo, S.; Incerti, M.; Bugatti, A.; Vacondio, F.; Barocelli, E.; Mor, M.; Pala, D.; Hassan-Mohamed, I.; Gioiello, A.; Rusnati, M.; Lodola, A.; Tognolini, M. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem. Pharmacol., 2016, 99, 18-30.
[http://dx.doi.org/10.1016/j.bcp.2015.10.006] [PMID: 26462575]
[42]
Hassan-Mohamed, I.; Giorgio, C.; Incerti, M.; Russo, S.; Pala, D.; Pasquale, E.B.; Zanotti, I.; Vicini, P.; Barocelli, E.; Rivara, S.; Mor, M.; Lodola, A.; Tognolini, M. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br. J. Pharmacol., 2014, 171(23), 5195-5208.
[http://dx.doi.org/10.1111/bph.12669] [PMID: 24597515]
[43]
Jackson, D.; Gooya, J.; Mao, S.; Kinneer, K.; Xu, L.; Camara, M.; Fazenbaker, C.; Fleming, R.; Swamynathan, S.; Meyer, D.; Senter, P.D.; Gao, C.; Wu, H.; Kinch, M.; Coats, S.; Kiener, P.A.; Tice, D.A. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res., 2008, 68(22), 9367-9374.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-1933] [PMID: 19010911]
[44]
Riedl, S.; Pasquale, E. Targeting the Eph system with peptides and peptide conjugates. Curr. Drug Targets, 2015, 16(10), 1031-1047.
[http://dx.doi.org/10.2174/1389450116666150727115934] [PMID: 26212263]
[45]
Noberini, R.; Lamberto, I.; Pasquale, E.B. Targeting Eph receptors with peptides and small molecules: Progress and challenges. Semin. Cell Dev. Biol., 2012, 23(1), 51-57.
[http://dx.doi.org/10.1016/j.semcdb.2011.10.023] [PMID: 22044885]
[46]
Koolpe, M.; Dail, M.; Pasquale, E.B. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem., 2002, 277(49), 46974-46979.
[http://dx.doi.org/10.1074/jbc.M208495200] [PMID: 12351647]
[47]
Mitra, S.; Duggineni, S.; Koolpe, M.; Zhu, X.; Huang, Z.; Pasquale, E.B. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry, 2010, 49(31), 6687-6695.
[http://dx.doi.org/10.1021/bi1006223] [PMID: 20677833]
[48]
Wu, B.; Wang, S.; De, S.K.; Barile, E.; Quinn, B.A.; Zharkikh, I.; Purves, A.; Stebbins, J.L.; Oshima, R.G.; Fisher, P.B.; Pellecchia, M. Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer cells. Chem. Biol., 2015, 22(7), 876-887.
[http://dx.doi.org/10.1016/j.chembiol.2015.06.011] [PMID: 26165155]
[49]
Salem, A.F.; Wang, S.; Billet, S.; Chen, J.F.; Udompholkul, P.; Gambini, L.; Baggio, C.; Tseng, H.R.; Posadas, E.M.; Bhowmick, N.A.; Pellecchia, M. Reduction of circulating cancer cells and metastases in breast-cancer models by a potent EphA2-agonistic peptide–drug conjugate. J. Med. Chem., 2018, 61(5), 2052-2061.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01837] [PMID: 29470068]
[50]
Udompholkul, P.; Baggio, C.; Gambini, L.; Sun, Y.; Zhao, M.; Hoffman, R.M.; Pellecchia, M. Effective tumor targeting by EphA2-agonist-biotin-streptavidin conjugates. Molecules, 2021, 26(12), 3687.
[http://dx.doi.org/10.3390/molecules26123687] [PMID: 34204178]
[51]
Gambini, L.; Salem, A.F.; Udompholkul, P.; Tan, X.F.; Baggio, C.; Shah, N.; Aronson, A.; Song, J.; Pellecchia, M. Structure-based design of novel EphA2 agonistic agents with nanomolar affinity in vitro and in cell. ACS Chem. Biol., 2018, 13(9), 2633-2644.
[http://dx.doi.org/10.1021/acschembio.8b00556] [PMID: 30110533]
[52]
Wykosky, J.; Gibo, D.M.; Debinski, W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells. Mol. Cancer Ther., 2007, 6(12), 3208-3218.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-0200] [PMID: 18089715]
[53]
Kim, J.M.; Lin, C.; Stavre, Z.; Greenblatt, M.B.; Shim, J.H. Osteoblast-osteoclast communication and bone homeostasis. Cells, 2020, 9(9), 2073.
[http://dx.doi.org/10.3390/cells9092073] [PMID: 32927921]
[54]
Matsuo, K.; Otaki, N. Bone cell interactions through Eph/ephrin. Cell Adhes. Migr., 2012, 6(2), 148-156.
[http://dx.doi.org/10.4161/cam.20888] [PMID: 22660185]
[55]
Vaught, D.B.; Merkel, A.R.; Lynch, C.C.; Edwards, J.; Tantawy, M.N.; Hilliard, T.; Wang, S.; Peterson, T.; Johnson, R.W.; Sterling, J.A.; Brantley-Sieders, D. EphA2 is a clinically relevant target for breast cancer bone metastatic disease. JBMR Plus, 2021, 5(4), e10465.
[http://dx.doi.org/10.1002/jbm4.10465] [PMID: 33869989]
[56]
Murugan, S.; Cheng, C. Roles of Eph-ephrin signaling in the eye lens cataractogenesis, biomechanics, and homeostasis. Front. Cell Dev. Biol., 2022, 10, 852236.
[http://dx.doi.org/10.3389/fcell.2022.852236] [PMID: 35295853]
[57]
Zhou, Y.; Bennett, T.M.; Ruzycki, P.A.; Shiels, A. Mutation of the EPHA2 tyrosine-kinase domain dysregulates cell pattern formation and cytoskeletal gene expression in the lens. Cells, 2021, 10(10), 2606.
[http://dx.doi.org/10.3390/cells10102606] [PMID: 34685586]
[58]
Cooper, M.A.; Son, A.I.; Komlos, D.; Sun, Y.; Kleiman, N.J.; Zhou, R. Loss of ephrin-A5 function disrupts lens fiber cell packing and leads to cataract. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(43), 16620-16625.
[http://dx.doi.org/10.1073/pnas.0808987105] [PMID: 18948590]
[59]
Liu, W.; Huang, D.; Guo, R.; Ji, J. Pathological changes of the anterior lens capsule. J. Ophthalmol., 2021, 2021, 9951032.
[http://dx.doi.org/10.1155/2021/9951032] [PMID: 34055399]
[60]
Cheng, C.; Gong, X. Diverse roles of Eph/ephrin signaling in the mouse lens. PLoS One, 2011, 6(11), e28147.
[http://dx.doi.org/10.1371/journal.pone.0028147] [PMID: 22140528]
[61]
Tan, W.; Hou, S.; Jiang, Z.; Hu, Z.; Yang, P.; Ye, J. Association of EPHA2 polymorphisms and age-related cortical cataract in a Han Chinese population. Mol. Vis., 2011, 17, 1553-1558.
[PMID: 21686326]
[62]
Sundaresan, P.; Ravindran, R.D.; Vashist, P.; Shanker, A.; Nitsch, D.; Talwar, B.; Maraini, G.; Camparini, M.; Nonyane, B.A.S.; Smeeth, L.; Chakravarthy, U.; Hejtmancik, J.F.; Fletcher, A.E. EPHA2 polymorphisms and age-related cataract in India. PLoS One, 2012, 7(3), e33001.
[http://dx.doi.org/10.1371/journal.pone.0033001] [PMID: 22412971]
[63]
Reis, L.M.; Tyler, R.C.; Semina, E.V. Identification of a novel C-terminal extension mutation in EPHA2 in a family affected with congenital cataract. Mol. Vis., 2014, 20, 836-842.
[PMID: 24940039]
[64]
Park, J.E.; Son, A.I.; Hua, R.; Wang, L.; Zhang, X.; Zhou, R. Human cataract mutations in EPHA2 SAM domain alter receptor stability and function. PLoS One, 2012, 7(5), e36564.
[http://dx.doi.org/10.1371/journal.pone.0036564] [PMID: 22570727]
[65]
Vincenzi, M.; Mercurio, F.A.; Leone, M. Sam domains in multiple diseases. Curr. Med. Chem., 2020, 27(3), 450-476.
[http://dx.doi.org/10.2174/0929867325666181009114445] [PMID: 30306850]
[66]
Mercurio, F.A.; Costantini, S.; Di Natale, C.; Pirone, L.; Guariniello, S.; Scognamiglio, P.L.; Marasco, D.; Pedone, E.M.; Leone, M. Structural investigation of a C-terminal EphA2 receptor mutant: Does mutation affect the structure and interaction properties of the Sam domain? Biochim. Biophys. Acta. Proteins Proteomics, 2017, 1865(9), 1095-1104.
[http://dx.doi.org/10.1016/j.bbapap.2017.06.003] [PMID: 28602916]
[67]
Cercone, M.A.; Schroeder, W.; Schomberg, S.; Carpenter, T.C. EphA2 receptor mediates increased vascular permeability in lung injury due to viral infection and hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol., 2009, 297(5), L856-L863.
[http://dx.doi.org/10.1152/ajplung.00118.2009] [PMID: 19684201]
[68]
Zhang, A.; Xing, J.; Xia, T.; Zhang, H.; Fang, M.; Li, S.; Du, Y.; Li, X.C.; Zhang, Z.; Zeng, M.S. EphA2 phosphorylates NLRP 3 and inhibits inflammasomes in airway epithelial cells. EMBO Rep., 2020, 21(7), e49666.
[http://dx.doi.org/10.15252/embr.201949666] [PMID: 32352641]
[69]
Lee, S.H.; Kang, S.H.; Han, M.S.; Kwak, J.W.; Kim, H.G.; Lee, T.H.; Lee, D.B.; Kim, T.H. The expression of ephrinA1/ephA2 receptor increases in chronic rhinosinusitis and ephrina1/epha2 signaling affects rhinovirus-induced innate immunity in human sinonasal epithelial cells. Front. Immunol., 2021, 12, 793517.
[http://dx.doi.org/10.3389/fimmu.2021.793517] [PMID: 34975898]
[70]
de Boer, E.C.W.; van Gils, J.M.; van Gils, M.J. Ephrin-Eph signaling usage by a variety of viruses. Pharmacol. Res., 2020, 159, 105038.
[http://dx.doi.org/10.1016/j.phrs.2020.105038] [PMID: 32565311]
[71]
Bossart, K.N.; Bingham, J.; Middleton, D. Targeted strategies for henipavirus therapeutics. Open Virol. J., 2007, 1(1), 14-25.
[http://dx.doi.org/10.2174/1874357900701010014] [PMID: 19440455]
[72]
Wang, J.; Zheng, X.; Peng, Q.; Zhang, X.; Qin, Z. Eph receptors: The bridge linking host and virus. Cell. Mol. Life Sci., 2020, 77(12), 2355-2365.
[http://dx.doi.org/10.1007/s00018-019-03409-6] [PMID: 31893311]
[73]
Jilg, N.; Chung, R.T. Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C. J. Hepatol., 2012, 56(1), 282-284.
[http://dx.doi.org/10.1016/j.jhep.2011.06.020] [PMID: 21784050]
[74]
Harris, H.J.; Farquhar, M.J.; Mee, C.J.; Davis, C.; Reynolds, G.M.; Jennings, A.; Hu, K.; Yuan, F.; Deng, H.; Hubscher, S.G.; Han, J.H.; Balfe, P.; McKeating, J.A. CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry. J. Virol., 2008, 82(10), 5007-5020.
[http://dx.doi.org/10.1128/JVI.02286-07] [PMID: 18337570]
[75]
Atkins, C.; Evans, C.W.; Nordin, B.; Patricelli, M.P.; Reynolds, R.; Wennerberg, K.; Noah, J.W. Global human-kinase screening identifies therapeutic host targets against influenza. SLAS Discov., 2014, 19(6), 936-946.
[http://dx.doi.org/10.1177/1087057113518068] [PMID: 24464431]
[76]
Rani, A.; Jakhmola, S.; Karnati, S.; Parmar, H.S.; Chandra Jha, H. Potential entry receptors for human γ-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections. Tumour Virus Res., 2021, 12, 200227.
[http://dx.doi.org/10.1016/j.tvr.2021.200227] [PMID: 34800753]
[77]
Blumenthal, M.J.; Schutz, C.; Meintjes, G.; Mohamed, Z.; Mendelson, M.; Ambler, J.M.; Whitby, D.; Mackelprang, R.D.; Carse, S.; Katz, A.A.; Schäfer, G. EPHA2 sequence variants are associated with susceptibility to Kaposi’s sarcoma-associated herpesvirus infection and Kaposi’s sarcoma prevalence in HIV-infected patients. Cancer Epidemiol., 2018, 56, 133-139.
[http://dx.doi.org/10.1016/j.canep.2018.08.005] [PMID: 30176543]
[78]
Ganem, D. KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J. Clin. Invest., 2010, 120(4), 939-949.
[http://dx.doi.org/10.1172/JCI40567] [PMID: 20364091]
[79]
Chakraborty, S.; Veettil, M.V.; Bottero, V.; Chandran, B. Kaposi’s sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc. Natl. Acad. Sci. USA., 2012, 109(19), E1163-E1172.
[http://dx.doi.org/10.1073/pnas.1119592109] [PMID: 22509030]
[80]
Boshoff, C. Ephrin receptor: A door to KSHV infection. Nat. Med., 2012, 18(6), 861-863.
[http://dx.doi.org/10.1038/nm.2803] [PMID: 22673996]
[81]
Kumar, B.; Roy, A.; Veettil, M.V.; Chandran, B. Insight into the roles of E3 ubiquitin ligase c-Cbl, ESCRT machinery, and host cell signaling in Kaposi’s sarcoma-associated herpesvirus entry and trafficking. J. Virol., 2018, 92(4), e01376-17.
[http://dx.doi.org/10.1128/JVI.01376-17] [PMID: 29167336]
[82]
Veettil, M.; Bandyopadhyay, C.; Dutta, D.; Chandran, B. Interaction of KSHV with host cell surface receptors and cell entry. Viruses, 2014, 6(10), 4024-4046.
[http://dx.doi.org/10.3390/v6104024] [PMID: 25341665]
[83]
Kumar, B.; Chandran, B. KSHV entry and trafficking in target cells—hijacking of cell signal pathways, actin and membrane dynamics. Viruses, 2016, 8(11), 305.
[http://dx.doi.org/10.3390/v8110305] [PMID: 27854239]
[84]
Bandyopadhyay, C.; Valiya-Veettil, M.; Dutta, D.; Chakraborty, S.; Chandran, B. CIB1 synergizes with EphrinA2 to regulate Kaposi’s sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells. PLoS Pathog., 2014, 10(2), e1003941.
[http://dx.doi.org/10.1371/journal.ppat.1003941] [PMID: 24550731]
[85]
Wang, X.; Zou, Z.; Deng, Z.; Liang, D.; Zhou, X.; Sun, R.; Lan, K. Male hormones activate EphA2 to facilitate Kaposi’s sarcoma-associated herpesvirus infection: Implications for gender disparity in Kaposi’s sarcoma. PLoS Pathog., 2017, 13(9), e1006580.
[http://dx.doi.org/10.1371/journal.ppat.1006580] [PMID: 28957431]
[86]
TerBush, A.A.; Hafkamp, F.; Lee, H.J.; Coscoy, L. A kaposi’s sarcoma-associated herpesvirus infection mechanism is independent of integrins α3β1, αVβ3, and αVβ5. J. Virol., 2018, 92(17), e00803-18.
[http://dx.doi.org/10.1128/JVI.00803-18] [PMID: 29899108]
[87]
Hahn, A.S.; Kaufmann, J.K.; Wies, E.; Naschberger, E.; Panteleev-Ivlev, J.; Schmidt, K.; Holzer, A.; Schmidt, M.; Chen, J.; König, S.; Ensser, A.; Myoung, J.; Brockmeyer, N.H.; Stürzl, M.; Fleckenstein, B.; Neipel, F. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi’s sarcoma–associated herpesvirus. Nat. Med., 2012, 18(6), 961-966.
[http://dx.doi.org/10.1038/nm.2805] [PMID: 22635007]
[88]
Hahn, A.S.; Desrosiers, R.C. Binding of the Kaposi’s sarcoma-associated herpesvirus to the ephrin binding surface of the EphA2 receptor and its inhibition by a small molecule. J. Virol., 2014, 88(16), 8724-8734.
[http://dx.doi.org/10.1128/JVI.01392-14] [PMID: 24899181]
[89]
Fricke, T.; Großkopf, A.K.; Ensser, A.; Backovic, M.; Hahn, A.S. Antibodies targeting KSHV gH/gL reveal distinct neutralization mechanisms. Viruses, 2022, 14(3), 541.
[http://dx.doi.org/10.3390/v14030541] [PMID: 35336948]
[90]
Chen, W.; Sin, S.H.; Wen, K.W.; Damania, B.; Dittmer, D.P. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog., 2012, 8(11), e1003048.
[http://dx.doi.org/10.1371/journal.ppat.1003048] [PMID: 23209418]
[91]
Smatti, M.K.; Al-Sadeq, D.W.; Ali, N.H.; Pintus, G.; Abou-Saleh, H.; Nasrallah, G.K. Epstein–barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: An update. Front. Oncol., 2018, 8, 211.
[http://dx.doi.org/10.3389/fonc.2018.00211] [PMID: 29951372]
[92]
Cao, Y.; Xie, L.; Shi, F.; Tang, M.; Li, Y.; Hu, J.; Zhao, L.; Zhao, L.; Yu, X.; Luo, X.; Liao, W.; Bode, A.M. Targeting the signaling in Epstein–Barr virus-associated diseases: Mechanism, regulation, and clinical study. Signal Transduct. Target. Ther., 2021, 6(1), 15.
[http://dx.doi.org/10.1038/s41392-020-00376-4] [PMID: 33436584]
[93]
Frappier, L. Epstein-Barr virus: Current questions and challenges. Tumour Virus Res., 2021, 12, 200218.
[http://dx.doi.org/10.1016/j.tvr.2021.200218] [PMID: 34052467]
[94]
Soldan, S.S.; Lieberman, P.M. Epstein–Barr virus and multiple sclerosis. Nat. Rev. Microbiol., 2023, 21(1), 51-64.
[http://dx.doi.org/10.1038/s41579-022-00770-5] [PMID: 35931816]
[95]
Bu, G.L.; Xie, C.; Kang, Y.F.; Zeng, M.S.; Sun, C. How EBV infects: The tropism and underlying molecular mechanism for viral infection. Viruses, 2022, 14(11), 2372.
[http://dx.doi.org/10.3390/v14112372] [PMID: 36366470]
[96]
Zhu, Q.Y.; Shan, S.; Yu, J.; Peng, S.Y.; Sun, C.; Zuo, Y.; Zhong, L.Y.; Yan, S.M.; Zhang, X.; Yang, Z.; Peng, Y.J.; Shi, X.; Cao, S.M.; Wang, X.; Zeng, M.S.; Zhang, L. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Nat. Commun., 2021, 12(1), 6624.
[http://dx.doi.org/10.1038/s41467-021-26912-6] [PMID: 34785638]
[97]
Hutt-Fletcher, L.M. Epstein-Barr virus entry. J. Virol., 2007, 81(15), 7825-7832.
[http://dx.doi.org/10.1128/JVI.00445-07] [PMID: 17459936]
[98]
Campadelli-Fiume, G.; Collins-McMillen, D.; Gianni, T.; Yurochko, A.D. Integrins as herpesvirus receptors and mediators of the host signalosome. Annu. Rev. Virol., 2016, 3(1), 215-236.
[http://dx.doi.org/10.1146/annurev-virology-110615-035618] [PMID: 27501260]
[99]
Chen, Y.; Cao, A.; Li, Q.; Quan, J. Identification of DNA aptamers that specifically targets EBV+ nasopharyngeal carcinoma via binding with EphA2/CD98hc complex. Biochem. Biophys. Res. Commun., 2022, 608, 135-141.
[http://dx.doi.org/10.1016/j.bbrc.2022.03.157] [PMID: 35397426]
[100]
Kanno-Okada, H.; Takahashi, K.; Katano, H.; Shimizu, A.; Takakuwa, E.; Miyamoto, S.; Abiko, S.; Yamamoto, K.; Shimoda, T.; Mitsuhashi, T.; Hasegawa, H.; Matsuno, Y. A case of Epstein–Barr virus-associated lymphoepithelioma-like carcinoma of the colon. Pathol. Int., 2021, 71(6), 420-426.
[http://dx.doi.org/10.1111/pin.13095] [PMID: 33792098]
[101]
Fekadu, S.; Kanehiro, Y.; Kartika, A.V.; Hamada, K.; Sakurai, N.; Mizote, T.; Akada, J.; Yamaoka, Y.; Iizasa, H.; Yoshiyama, H. Gastric epithelial attachment of Helicobacter pylori induces EphA2 and NMHC-IIA receptors for Epstein-Barr virus. Cancer Sci., 2021, 112(11), 4799-4811.
[http://dx.doi.org/10.1111/cas.15121] [PMID: 34449934]
[102]
Wallaschek, N.; Reuter, S.; Silkenat, S.; Wolf, K.; Niklas, C.; Kayisoglu, Ö.; Aguilar, C.; Wiegering, A.; Germer, C.T.; Kircher, S.; Rosenwald, A.; Shannon-Lowe, C.; Bartfeld, S. Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids. PLoS Pathog., 2021, 17(2), e1009210.
[http://dx.doi.org/10.1371/journal.ppat.1009210] [PMID: 33596248]
[103]
Manns, M.P.; Maasoumy, B. Breakthroughs in hepatitis C research: From discovery to cure. Nat. Rev. Gastroenterol. Hepatol., 2022, 19(8), 533-550.
[http://dx.doi.org/10.1038/s41575-022-00608-8] [PMID: 35595834]
[104]
Rabaan, A.A.; Al-Ahmed, S.H.; Bazzi, A.M.; Alfouzan, W.A.; Alsuliman, S.A.; Aldrazi, F.A.; Haque, S. Overview of hepatitis C infection, molecular biology, and new treatment. J. Infectiology Public Health, 2020, 13(5), 773-783.
[http://dx.doi.org/10.1016/j.jiph.2019.11.015] [PMID: 31870632]
[105]
Colpitts, C.C.; Lupberger, J.; Doerig, C.; Baumert, T.F. Host cell kinases and the hepatitis C virus life cycle. Biochim. Biophys. Acta. Proteins Proteomics, 2015, 1854(10), 1657-1662.
[http://dx.doi.org/10.1016/j.bbapap.2015.04.011] [PMID: 25896387]
[106]
Crouchet, E.; Wrensch, F.; Schuster, C.; Zeisel, M.B.; Baumert, T.F. Host-targeting therapies for hepatitis C virus infection: Current developments and future applications. Therap. Adv. Gastroenterol., 2018, 11, 1756284818759483.
[http://dx.doi.org/10.1177/1756284818759483] [PMID: 29619090]
[107]
Scheel, T.K.H.; Rice, C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med., 2013, 19(7), 837-849.
[http://dx.doi.org/10.1038/nm.3248] [PMID: 23836234]
[108]
Colpitts, C.C.; El-Saghire, H.; Pochet, N.; Schuster, C.; Baumert, T.F. High-throughput approaches to unravel hepatitis C virus-host interactions. Virus Res., 2016, 218, 18-24.
[http://dx.doi.org/10.1016/j.virusres.2015.09.013] [PMID: 26410623]
[109]
Jeulin, H.; Velay, A.; Murray, J.; Schvoerer, E. Clinical impact of hepatitis B and C virus envelope glycoproteins. World J. Gastroenterol., 2013, 19(5), 654-664.
[http://dx.doi.org/10.3748/wjg.v19.i5.654] [PMID: 23429668]
[110]
Gerold, G.; Rice, C.M. Locking out hepatitis C. Nat. Med., 2011, 17(5), 542-544.
[http://dx.doi.org/10.1038/nm0511-542] [PMID: 21546968]
[111]
Tsai, E. Review of current and potential treatments for chronic hepatitis B virus infection. Gastroenterol. Hepatol. (N. Y.), 2021, 17(8), 367-376.
[PMID: 34602899]
[112]
Vincenzi, M.; Leone, M. The fight against human viruses: How NMR can help? Curr. Med. Chem., 2021, 28(22), 4380-4453.
[http://dx.doi.org/10.2174/0929867328666201228123748] [PMID: 33371830]
[113]
Tian, J.; Liu, W.; Zhang, Z.; Tang, L.; Li, D.; Tian, Z.; Lin, S.; Li, Y. Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2. J. Viral Hepat., 2019, 26(4), 496-505.
[http://dx.doi.org/10.1111/jvh.13048] [PMID: 30521133]
[114]
Wang, Y.; Zhang, Z.; Zhu, Z.; Wang, P.; Zhang, J.; Liu, H.; Li, J. The significance of EphA2-regulated Wnt/β-catenin signal pathway in promoting the metastasis of HBV-related hepatocellular carcinoma. Mol. Biol. Rep., 2023, 50(1), 565-575.
[http://dx.doi.org/10.1007/s11033-022-08045-1] [PMID: 36350420]
[115]
Shang, Z.; Kouznetsova, V.; Tsigelny, I. Human Papillomavirus (HPV) viral proteins substitute for the impact of somatic mutations by affecting cancer-related genes: Meta-analysis and perspectives. J. Infect., 2020, 3(1), 29-47.
[http://dx.doi.org/10.29245/2689-9981/2020/1.1157]
[116]
Seiwert, T.Y.; Zuo, Z.; Keck, M.K.; Khattri, A.; Pedamallu, C.S.; Stricker, T.; Brown, C.; Pugh, T.J.; Stojanov, P.; Cho, J.; Lawrence, M.S.; Getz, G.; Brägelmann, J.; DeBoer, R.; Weichselbaum, R.R.; Langerman, A.; Portugal, L.; Blair, E.; Stenson, K.; Lingen, M.W.; Cohen, E.E.W.; Vokes, E.E.; White, K.P.; Hammerman, P.S. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res., 2015, 21(3), 632-641.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3310] [PMID: 25056374]
[117]
Goudsmit, C.; da Veiga Leprevost, F.; Basrur, V.; Peters, L.; Nesvizhskii, A.; Walline, H. Differences in extracellular vesicle protein cargo are dependent on head and neck squamous cell carcinoma cell of origin and human papillomavirus status. Cancers (Basel), 2021, 13(15), 3714.
[http://dx.doi.org/10.3390/cancers13153714] [PMID: 34359613]
[118]
Li, X.; Li, D.; Ma, R. ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway. Oncol. Lett., 2022, 23(4), 129.
[http://dx.doi.org/10.3892/ol.2022.13249] [PMID: 35251349]
[119]
Wang, Y.Q.; Zhao, X.Y. Human cytomegalovirus primary infection and reactivation: Insights from virion-carried molecules. Front. Microbiol., 2020, 11, 1511.
[http://dx.doi.org/10.3389/fmicb.2020.01511] [PMID: 32765441]
[120]
Griffiths, P.; Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol., 2021, 19(12), 759-773.
[http://dx.doi.org/10.1038/s41579-021-00582-z] [PMID: 34168328]
[121]
Wass, A.B.; Krishna, B.A.; Herring, L.E.; Gilbert, T.S.K.; Nukui, M.; Groves, I.J.; Dooley, A.L.; Kulp, K.H.; Matthews, S.M.; Rotroff, D.M.; Graves, L.M.; O’Connor, C.M. Cytomegalovirus US28 regulates cellular EphA2 to maintain viral latency. Sci. Adv., 2022, 8(43), eadd1168.
[http://dx.doi.org/10.1126/sciadv.add1168] [PMID: 36288299]
[122]
Dong, X.D.; Li, Y.; Li, Y.; Sun, C.; Liu, S.X.; Duan, H.; Cui, R.; Zhong, Q.; Mou, Y.G.; Wen, L.; Yang, B.; Zeng, M.S.; Luo, M.H.; Zhang, H. EphA2 is a functional entry receptor for HCMV infection of glioblastoma cells. PLoS Pathog., 2023, 19(5), e1011304.
[http://dx.doi.org/10.1371/journal.ppat.1011304] [PMID: 37146061]
[123]
Hahn, A.S.; Desrosiers, R.C. Rhesus monkey rhadinovirus uses eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog., 2013, 9(5), e1003360.
[http://dx.doi.org/10.1371/journal.ppat.1003360] [PMID: 23696734]
[124]
Bizot, E.; Bousquet, A.; Charpié, M.; Coquelin, F.; Lefevre, S.; Le Lorier, J.; Patin, M.; Sée, P.; Sarfati, E.; Walle, S.; Visseaux, B.; Basmaci, R. Rhinovirus: A narrative review on its genetic characteristics, pediatric clinical presentations, and pathogenesis. Front Pediatr., 2021, 9, 643219.
[http://dx.doi.org/10.3389/fped.2021.643219] [PMID: 33829004]
[125]
Esneau, C.; Duff, A.C.; Bartlett, N.W. Understanding rhinovirus circulation and impact on illness. Viruses, 2022, 14(1), 141.
[http://dx.doi.org/10.3390/v14010141] [PMID: 35062345]
[126]
Vincenzi, M.; Mercurio, F.A.; Leone, M. Looking for SARS-CoV-2 therapeutics through computational approaches. Curr. Med. Chem., 2022, 30(28), 3158-3214.
[PMID: 36200217]
[127]
Zhang, W.; Zhao, Y.; Zhang, F.; Wang, Q.; Li, T.; Liu, Z.; Wang, J.; Qin, Y.; Zhang, X.; Yan, X.; Zeng, X.; Zhang, S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol., 2020, 214, 108393.
[http://dx.doi.org/10.1016/j.clim.2020.108393] [PMID: 32222466]
[128]
Weisberg, E.; Parent, A.; Yang, P.L.; Sattler, M.; Liu, Q.; Liu, Q.; Wang, J.; Meng, C.; Buhrlage, S.J.; Gray, N.; Griffin, J.D. Repurposing of kinase inhibitors for treatment of COVID-19. Pharm. Res., 2020, 37(9), 167.
[http://dx.doi.org/10.1007/s11095-020-02851-7] [PMID: 32778962]
[129]
Galimberti, S.; Petrini, M.; Baratè, C.; Ricci, F.; Balducci, S.; Grassi, S.; Guerrini, F.; Ciabatti, E.; Mechelli, S.; Di Paolo, A.; Baldini, C.; Baglietto, L.; Macera, L.; Spezia, P.G.; Maggi, F. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2. Front. Oncol., 2020, 10, 1428.
[http://dx.doi.org/10.3389/fonc.2020.01428] [PMID: 33014780]
[130]
Carpenter, T.C.; Schroeder, W.; Stenmark, K.R.; Schmidt, E.P. Eph-A2 promotes permeability and inflammatory responses to bleomycin-induced lung injury. Am. J. Respir. Cell Mol. Biol., 2012, 46(1), 40-47.
[http://dx.doi.org/10.1165/rcmb.2011-0044OC] [PMID: 21799118]
[131]
Qiao, Q.; Liu, X.; Yang, T.; Cui, K.; Kong, L.; Yang, C.; Zhang, Z. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design. Acta Pharm. Sin. B, 2021, 11(10), 3060-3091.
[http://dx.doi.org/10.1016/j.apsb.2021.04.023] [PMID: 33977080]
[132]
Patil, M.A.; Upadhyay, A.K.; Hernandez-Lagunas, L.; Good, R.; Carpenter, T.C.; Sucharov, C.C.; Nozik-Grayck, E.; Kompella, U.B. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature. Artif. Cells Nanomed. Biotechnol., 2018, 46(3), S1059-S1066.
[http://dx.doi.org/10.1080/21691401.2018.1528984] [PMID: 30450979]
[133]
Ahsan, N.; Rao, R.S.P.; Wilson, R.S.; Punyamurtula, U.; Salvato, F.; Petersen, M.; Ahmed, M.K.; Abid, M.R.; Verburgt, J.C.; Kihara, D.; Yang, Z.; Fornelli, L.; Foster, S.B.; Ramratnam, B. Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches. Proteomics, 2021, 21(10), 2000279.
[http://dx.doi.org/10.1002/pmic.202000279] [PMID: 33860983]
[134]
Appelberg, S.; Gupta, S.; Svensson Akusjärvi, S.; Ambikan, A.T.; Mikaeloff, F.; Saccon, E.; Végvári, Á.; Benfeitas, R.; Sperk, M.; Ståhlberg, M.; Krishnan, S.; Singh, K.; Penninger, J.M.; Mirazimi, A.; Neogi, U. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg. Microbes Infect., 2020, 9(1), 1748-1760.
[http://dx.doi.org/10.1080/22221751.2020.1799723] [PMID: 32691695]
[135]
Bojkova, D.; Klann, K.; Koch, B.; Widera, M.; Krause, D.; Ciesek, S.; Cinatl, J.; Münch, C. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature, 2020, 583(7816), 469-472.
[http://dx.doi.org/10.1038/s41586-020-2332-7] [PMID: 32408336]
[136]
Zecha, J.; Lee, C.Y.; Bayer, F.P.; Meng, C.; Grass, V.; Zerweck, J.; Schnatbaum, K.; Michler, T.; Pichlmair, A.; Ludwig, C.; Kuster, B. Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing. Mol. Cell. Proteomics, 2020, 19(9), 1503-1522.
[http://dx.doi.org/10.1074/mcp.RA120.002164] [PMID: 32591346]
[137]
Stukalov, A.; Girault, V.; Grass, V.; Karayel, O.; Bergant, V.; Urban, C.; Haas, D.A.; Huang, Y.; Oubraham, L.; Wang, A.; Hamad, M.S.; Piras, A.; Hansen, F.M.; Tanzer, M.C.; Paron, I.; Zinzula, L.; Engleitner, T.; Reinecke, M.; Lavacca, T.M.; Ehmann, R.; Wölfel, R.; Jores, J.; Kuster, B.; Protzer, U.; Rad, R.; Ziebuhr, J.; Thiel, V.; Scaturro, P.; Mann, M.; Pichlmair, A. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature, 2021, 594(7862), 246-252.
[http://dx.doi.org/10.1038/s41586-021-03493-4] [PMID: 33845483]
[138]
Hekman, R.M.; Hume, A.J.; Goel, R.K.; Abo, K.M.; Huang, J.; Blum, B.C.; Werder, R.B.; Suder, E.L.; Paul, I.; Phanse, S.; Youssef, A.; Alysandratos, K.D.; Padhorny, D.; Ojha, S.; Mora-Martin, A.; Kretov, D.; Ash, P.E.A.; Verma, M.; Zhao, J.; Patten, J.J.; Villacorta-Martin, C.; Bolzan, D.; Perea-Resa, C.; Bullitt, E.; Hinds, A.; Tilston-Lunel, A.; Varelas, X.; Farhangmehr, S.; Braunschweig, U.; Kwan, J.H.; McComb, M.; Basu, A.; Saeed, M.; Perissi, V.; Burks, E.J.; Layne, M.D.; Connor, J.H.; Davey, R.; Cheng, J.X.; Wolozin, B.L.; Blencowe, B.J.; Wuchty, S.; Lyons, S.M.; Kozakov, D.; Cifuentes, D.; Blower, M.; Kotton, D.N.; Wilson, A.A.; Mühlberger, E.; Emili, A. Actionable cytopathogenic host responses of human alveolar type 2 cells to SARS-CoV-2. Mol. Cell, 2021, 81(1), 212.
[http://dx.doi.org/10.1016/j.molcel.2020.12.028] [PMID: 33417854]
[139]
Klann, K.; Bojkova, D.; Tascher, G.; Ciesek, S.; Münch, C.; Cinatl, J. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol. Cell, 2020, 80(1), 164-174.e4.
[http://dx.doi.org/10.1016/j.molcel.2020.08.006] [PMID: 32877642]
[140]
Laurent, E.M.N.; Sofianatos, Y.; Komarova, A.; Gimeno, J.P.; Tehrani, P.S.; Kim, D.K.; Abdouni, H.; Duhamel, M.; Cassonnet, P.; Knapp, J.J.; Kuang, D.; Chawla, A.; Sheykhkarimli, D.; Rayhan, A.; Li, R.; Pogoutse, O.; Hill, D.E.; Calderwood, M.A.; Falter-Braun, P.; Aloy, P.; Stelzl, U.; Vidal, M.; Gingras, A.C.; Pavlopoulos, G.A.; Van Der Werf, S.; Fournier, I.; Roth, F.P.; Salzet, M.; Demeret, C.; Jacob, Y.; Coyaud, E. Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms. bioRxiv, 2020.
[http://dx.doi.org/10.1101/2020.08.28.272955]
[141]
Samavarchi-Tehrani, P.; Abdouni, H.; Knight, J.D.R.; Astori, A.; Samson, R.; Lin, Z-Y.; Kim, D-K.; Knapp, J.J.; St-Germain, J.; Go, C.D.; Larsen, B.; Wong, C.J.; Cassonnet, P.; Demeret, C.; Jacob, Y.; Roth, F.P.; Raught, B.; Gingras, A-C.A. SARS-CoV-2 - host proximity interactome. bioRxiv, 2020.
[142]
St-Germain, J.R.; Astori, A.; Samavarchi-Tehrani, P.; Abdouni, H.; Macwan, V.; Kim, D-K.; Knapp, J.J.; Roth, F.P.; Gingras, A.C.; Raught, B.A. SARS-CoV-2 BioID-based virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-19 research. bioRxiv, 2020.
[http://dx.doi.org/10.1101/2020.08.28.269175]
[143]
Datta, S.; Tavares, A.H.; Reyes-Robles, T.; Ryu, K.A.; Khan, N.; Bechtel, T.J.; Bertoch, J.M.; White, C.H.; Hazuda, D.J.; Vora, K.A.; Hett, E.C.; Fadeyi, O.O.; Oslund, R.C.; Saeed, M.; Emili, A. High resolution photocatalytic mapping of SARS-CoV-2 Spike protein-host cell membrane interactions. bioRxiv, 2022.
[http://dx.doi.org/10.1101/2022.09.02.506438]
[144]
Liu, X.; Huuskonen, S.; Laitinen, T.; Redchuk, T.; Bogacheva, M.; Salokas, K.; Pöhner, I.; Öhman, T.; Tonduru, A.K.; Hassinen, A.; Gawriyski, L.; Keskitalo, S.; Vartiainen, M.K.; Pietiäinen, V.; Poso, A.; Varjosalo, M. SARS-CoV-2–host proteome interactions for antiviral drug discovery. Mol. Syst. Biol., 2021, 17(11), e10396.
[http://dx.doi.org/10.15252/msb.202110396] [PMID: 34709727]
[145]
EPHA2. Available from: https://thebiogrid.org/108288/summary/homo-sapiens/epha2.html
[146]
Oughtred, R.; Rust, J.; Chang, C.; Breitkreutz, B.J.; Stark, C.; Willems, A.; Boucher, L.; Leung, G.; Kolas, N.; Zhang, F.; Dolma, S.; Coulombe-Huntington, J.; Chatr-aryamontri, A.; Dolinski, K.; Tyers, M. The BIOGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci., 2021, 30(1), 187-200.
[http://dx.doi.org/10.1002/pro.3978] [PMID: 33070389]
[147]
Garg, A.; Kumar, G.; Sinha, S. New insights into nCOVID-19 binding domain and its cellular receptors. bioRxiv, 2020.
[http://dx.doi.org/10.1101/2020.09.06.285023]
[148]
Zalpoor, H.; Akbari, A.; Samei, A.; Forghaniesfidvajani, R.; Kamali, M.; Afzalnia, A.; Manshouri, S.; Heidari, F.; Pornour, M.; Khoshmirsafa, M.; Aazami, H.; Seif, F. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies. Cell. Mol. Biol. Lett., 2022, 27(1), 10.
[http://dx.doi.org/10.1186/s11658-022-00311-1] [PMID: 35109786]
[149]
McGill, J.R.; Lagassé, H.A.D.; Hernandez, N.; Hopkins, L.; Jankowski, W.; McCormick, Q.; Simhadri, V.; Golding, B.; Sauna, Z.E. A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection. Sci. Rep., 2022, 12(1), 11388.
[http://dx.doi.org/10.1038/s41598-022-15225-3] [PMID: 35794133]
[150]
Zalpoor, H.; Akbari, A.; Nabi-Afjadi, M. Ephrin (Eph) receptor and downstream signaling pathways: A promising potential targeted therapy for COVID-19 and associated cancers and diseases. Hum. Cell, 2022, 35(3), 952-954.
[http://dx.doi.org/10.1007/s13577-022-00697-2] [PMID: 35377105]
[151]
BioRender Templates. Available from: https://app.biorender.com/biorender-templates

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy